Active Fibronectin Type III Domain Containing Protein 5 (FNDC5)

FRCP2; Irisin; Fibronectin type III repeat-containing protein 2

ACTIVITY TEST

Fibronectin type III domain-containing protein 5, the precursor of irisin, is a protein that is encoded by the FNDC5 gene. It was reported that FNDC5 significantly decreased cell number, migration and viability through apoptosis in malignant MDA-MB-231 cells. Thus MDA-MB-231 cells were seeded overnight at a density of 5,000 cells/well, and treated with or without various concentrations of FNDC5 for 48h, then MDA-MB-231 cells were observed by inverted microscope and cell viability was measured by Cell Counting Kit-8 (CCK-8). Briefly, 10µL of CCK-8 solution was added to each well of the plate, then measure the absorbance at 450nm using a microplate reader after incubating the plate for 1-4 hours at 37oC.<br/>Cell apoptosis of MDA-MB-231 cells after incubation with FNDC5 for 48h observed by inverted microscope was shown in Figure 1.<br/>(A) MDA-MB-231 cells cultured in DMEM, stimulated with 4nM FNDC5 for 48h; <br/>(B) Unstimulated MDA-MB-231 cells cultured in DMEM for 48h.<br/>Figure. Cell apoptosis of MDA-MB-231 cells after stimulated with FNDC5.

The dose-effect curve of FNDC5 was shown in Figure 2. It was obvious that FNDC5 significantly decreased cell viability of MDA-MB-231 cells. The ED50 for this effect is typically 1.35~12.52ug/mL.<br/>Figure. The dose-effect curve of FNDC5 on MDA-MB-231 cells.

USAGE

Reconstitute in PBS (pH7.6) to a concentration of 0.1-1.0 mg/mL. Do not vortex.

STORAGE

Avoid repeated freeze/thaw cycles. Store at 2-8°C for one month. Aliquot and store at -80°C for 12 months.

STABILITY

The thermal stability is described by the loss rate. The loss rate was determined by accelerated thermal degradation test, that is, incubate the protein at 37°C for 48h, and no obvious degradation and precipitation were observed. The loss rate is less than 5% within the expiration date under appropriate storage condition.

GIVEAWAYS

INCREMENT SERVICES

Magazine Citations
Diabetes Research and Clinical Practice Serum irisin levels in new-onset type 2 diabetes PubMed: 23369227
Journal of diabetes and its complications Lower circulating irisin is associated with type 2 diabetes mellitus Pubmed: 23619195
Horm Metab Res. Inconsistency in circulating irisin levels: what is really happening Pubmed:24459033
Int J Obes (Lond). Leptin administration activates irisin-induced myogenesis via nitric oxide-dependent mechanisms, but reduces its effect on subcutaneous fat browning in mice Pubmed:25199621
Molecular and Cellular Endocrinology Fenofibrate (PPARalpha agonist) induces beige cell formation in subcutaneous white adipose tissue from diet-induced male obese mice Pubmed:25576856
journal of diabetes Lower irisin level in patients with type 2 diabetes mellitus: A case-control study and meta-analysis PubMed: 25494632
The Journal of Maternal-Fetal & Neonatal Medicine Maternal circulating levels of irisin in intrahepatic cholestasis of pregnancy PubMed: 26689349
Hormone and Metabolic Research Lower Circulating Irisin Level in Patients with Diabetes Mellitus: A Systematic Review and Meta-Analysis Pubmed:27300472
Nature Reviews Endocrinology Physiology and role of irisin in glucose homeostasis. pubmed:28211512
Journal of Molecular and Cellular Cardiology Irisin improves perivascular adipose tissue dysfunction via regulation of the heme oxygenase-1/adiponectin axis in diet-induced obese mice pubmed:27638193
Biochemical and Biophysical Research Communications Irisin stimulates cell proliferation and invasion by targeting the PI3K/AKT pathway in human hepatocellular carcinoma pubmed:28867187
PLoS One Differential actions of PPAR-α and PPAR-β/δ on beige adipocyte formation: A study in the subcutaneous white adipose tissue of obese male mice Pubmed:29351550
International Brazilian Journal of Urology The Diagnostic Value of FNDC5/Irisin in Renal Cell Cancer. Pubmed:29522296
Catalog No. Related products for research use of Homo sapiens (Human) Organism species Applications (RESEARCH USE ONLY!)
RPN576Hu02 Recombinant Fibronectin Type III Domain Containing Protein 5 (FNDC5) Positive Control; Immunogen; SDS-PAGE; WB.
EPN576Hu61 Eukaryotic Fibronectin Type III Domain Containing Protein 5 (FNDC5) Positive Control; Immunogen; SDS-PAGE; WB.
RPN576Hu03 Recombinant Fibronectin Type III Domain Containing Protein 5 (FNDC5) Positive Control; Immunogen; SDS-PAGE; WB.
RPN576Hu01 Recombinant Fibronectin Type III Domain Containing Protein 5 (FNDC5) Positive Control; Immunogen; SDS-PAGE; WB.
APN576Hu01 Active Fibronectin Type III Domain Containing Protein 5 (FNDC5) Cell culture; Activity Assays.
APN576Hu61 Active Fibronectin Type III Domain Containing Protein 5 (FNDC5) Cell culture; Activity Assays.
PAN576Hu02 Polyclonal Antibody to Fibronectin Type III Domain Containing Protein 5 (FNDC5) WB; IHC; ICC; IP.
PAN576Hu01 Polyclonal Antibody to Fibronectin Type III Domain Containing Protein 5 (FNDC5) WB; IHC; ICC; IP.
LAN576Hu71 Biotin-Linked Polyclonal Antibody to Fibronectin Type III Domain Containing Protein 5 (FNDC5) WB; IHC; ICC.
SEN576Hu ELISA Kit for Fibronectin Type III Domain Containing Protein 5 (FNDC5) Enzyme-linked immunosorbent assay for Antigen Detection.